Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Research & Development (2016 - 2025)

Tandem Diabetes Care's Research & Development history spans 13 years, with the latest figure at $46.1 million for Q4 2025.

  • For Q4 2025, Research & Development fell 11.75% year-over-year to $46.1 million; the TTM value through Dec 2025 reached $193.1 million, down 2.9%, while the annual FY2025 figure was $193.1 million, 2.9% down from the prior year.
  • Research & Development reached $46.1 million in Q4 2025 per TNDM's latest filing, down from $48.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $52.2 million in Q4 2024 to a low of $18.0 million in Q1 2021.
  • Average Research & Development over 5 years is $39.6 million, with a median of $42.4 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 84.62% in 2022, then dropped 11.75% in 2025.
  • A 5-year view of Research & Development shows it stood at $29.5 million in 2021, then increased by 20.66% to $35.6 million in 2022, then grew by 19.72% to $42.6 million in 2023, then increased by 22.52% to $52.2 million in 2024, then decreased by 11.75% to $46.1 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Research & Development are $46.1 million (Q4 2025), $48.7 million (Q3 2025), and $48.1 million (Q2 2025).